Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes
These salt forms of GLP-1s have not been proven safe and effective in humans or approved by the FDA, Basina noted, adding that effectiveness can be different due to the salt form differences. Additives To differentiate their products from the FDA-approved GLP-1s, many compounders add extra ingredients most commonly vitamin B12, but also B6, niacinamide, glycine or carnitine that have no proven benefit for weight loss or diabetes management
Available from: Bertoccini L, Baroni MG (2021) GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
A critical reassessment of historical failures reveals that many appetite-related peptide programs were abandoned not because their biology was flawed, but because early development conflated dose-dependent adverse effects or behavioral complexity with intrinsic target unsuitability (Lau et al., 2015
